Cracking cancers code feb 2014
New Paradigms for Clinical Drug Development in the Genomic Era Richard Simon, D.Sc. Chief, Biometric Research Branch National Cancer Institute .
FDA-Industry-Biomarkers.ppt
OpportunityAnalyzer: Bladder Cancer - Opportunity Analysis and Forecasts to 2017
Inter-site autism biomarkers from resting state fMRI
Clinical ImmunologyLI
Clinical Trial Support
An Update on Current Management of Advanced Renal Cell Cancer, Biomarkers and Future Directions
Clinical Trial Designs for the Evaluation of Prognostic & Predictive Classifiers Richard Simon, D.Sc. Chief, Biometric Research Branch National Cancer.
1 1 Review Experience in Evaluating Predictive Biomarkers – Design and Analysis Considerations Yuan-Li Shen, Dr. P.H. U.S. Food and Drug Administration.
CPCP Institute of Clinical Pharmacology The gap between biomarkers and surrogate endpoints Oncology Dr. Michael Zühlsdorf Bayer Healthcare AG Institute.
Moving from Correlative Science to Predictive Medicine Richard Simon, D.Sc. Chief, Biometric Research Branch National Cancer Institute .
